Ophthalmology. 2013 May;120(5 Suppl):S23-5. doi: 10.1016/j.ophtha.2013.01.059.
The treatment of neovascular age-related macular degeneration (AMD) had been revolutionized by the use of anti-vascular endothelial growth factor (VEGF) drugs: bevacizumab and ranibizumab. With the introduction of a third anti-VEGF drug, aflibercept, ophthalmologists have several options to choose from, as well as various treatment regimens they can follow. In this Interview, Jeffrey S. Heier, MD, of Ophthalmic Consultants of Boston, Massachusetts, discusses his approaches to managing the treatment of patients with AMD and providing them with individualized care.
抗血管内皮生长因子（VEGF）药物的应用彻底改变了新生血管性年龄相关性黄斑变性（AMD）的治疗：贝伐单抗和雷珠单抗。随着第三种抗 VEGF 药物阿柏西普的问世，眼科医生有了多种选择，以及他们可以遵循的各种治疗方案。在本次访谈中，来自马萨诸塞州波士顿眼科顾问公司的 Jeffrey S. Heier, MD 探讨了他在管理 AMD 患者的治疗和为他们提供个体化护理方面的方法。
